Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Amanat Acquisition Corp has completed the acquisition of a healthcare services other platform, based in New Jersey, for $75 million. The newly organized special purpose acquisition company is structured to pursue a healthcare M&A target, including healthcare-related industries, through a merger, share exchange, asset acquisition, or similar business combination. The company plans to execute NJ acquisitions focused on healthcare services other acquisition opportunities, aiming to identify operating businesses that fit its healthcare investment mandate. As a private equity acquisition vehicle, the platform acquisition is sized at $75 million and priced at $10.00 per Class A ordinary share, with an expected close on May 20, 2026, and a 45-day over-allotment option for up to 1,125,000 additional shares.
Filed under
Powered by Tentt
Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026